Immuneering Corporation (IMRX)

NASDAQ: IMRX · Real-Time Price · USD
2.105
+0.105 (5.25%)
Dec 23, 2024, 11:14 AM EST - Market open
5.25%
Market Cap 65.36M
Revenue (ttm) n/a
Net Income (ttm) -58.07M
Shares Out 31.05M
EPS (ttm) -1.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 209,060
Open 2.040
Previous Close 2.000
Day's Range 1.960 - 2.110
52-Week Range 1.000 - 7.920
Beta -0.33
Analysts Buy
Price Target 12.80 (+508.08%)
Earnings Date Nov 13, 2024

About IMRX

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridg... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 68
Stock Exchange NASDAQ
Ticker Symbol IMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for IMRX stock is "Buy." The 12-month stock price forecast is $12.8, which is an increase of 508.08% from the latest price.

Price Target
$12.8
(508.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immuneering Launches Pancreatic Cancer Advisory Board

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- a...

4 days ago - GlobeNewsWire

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settl...

Other symbols: FOLD
9 days ago - Benzinga

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 ...

11 days ago - GlobeNewsWire

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad...

26 days ago - GlobeNewsWire

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Design...

5 weeks ago - GlobeNewsWire

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line

3 months ago - GlobeNewsWire

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 - - Granted FDA Fast Track Designation for IMM-1-104 in First-li...

4 months ago - GlobeNewsWire

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104's path to U.S. FDA su...

5 months ago - GlobeNewsWire

Immuneering to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad ...

7 months ago - GlobeNewsWire

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Tri...

8 months ago - GlobeNewsWire

Immuneering Recognizes Melanoma Awareness Month

- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 -...

8 months ago - GlobeNewsWire

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibit...

9 months ago - GlobeNewsWire

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

9 months ago - GlobeNewsWire

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion o...

9 months ago - GlobeNewsWire

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort resul...

9 months ago - Seeking Alpha

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ct...

10 months ago - GlobeNewsWire

Immuneering Appoints Thomas J. Schall, Ph.D.

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

10 months ago - GlobeNewsWire

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) -

10 months ago - GlobeNewsWire

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on devel...

Other symbols: BLRXCADLONCY
10 months ago - Newsfile Corp

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

10 months ago - GlobeNewsWire

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

10 months ago - GlobeNewsWire

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected i...

10 months ago - GlobeNewsWire

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

– Fast Track designation has the potential to accelerate lead asset IMM-1-104's path to U.S. FDA submission for pancreatic ductal adenocarcinoma –

10 months ago - GlobeNewsWire

Immuneering Announces Participation in February Investor Conferences

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of ca...

11 months ago - GlobeNewsWire

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 - CAMBRIDGE, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncolog...

1 year ago - GlobeNewsWire